ADA

Studies summarized in this slide show focus on fine-tuning insulin-containing regimens to enhance glucose control and avoid variability.

Glycemic variability fuels hypoglycemia but in one study from ADA 2017 is found to actually help predict hypoglycemic events.

Cardiovascular risk/benefit profiles of pioglitazone and the SGLT2 inhibitor class are summarized, based on reports at ADA 2017.

A1C vs FPG to diagnose prediabetes; prediabetes and CHF; and how much weight loss is too much? Reports from ADA 2017.

Insulin degludec vs glargine--which costs less per anum and why? We summarize this study and 2 other direct insulin comparisons reported at ADA 2017.

When to start screening for B12 deficiency in your diabetes patients taking metformin? We review a dose-response diet study plus 2 others on oral drugs.

A how-to overview of how to advance therapy for hyperglycemia and ASCVD risk factors in patients with T2DM.

Self-monitoring of blood glucose is critical for all patients with T2DM and their physicians.The numbers help modify behavior and Rx.

Seven top diabetes apps for PCPs include insulin calculators, Rx algorithms, comorbidity support, and patient tracking tools.

Improvement in overall diet quality lowers the risk of type 2 diabetes, a new study shows. This is independent of other healthful behaviors, including increased physical activity and body weight loss.